Industry news
-
Favipiravir in Russia Received Permission for Outpatient Use
24 September 2020
Russia’s Healthcare Ministry has allowed the use of two favipiravir preparations for outpatient treatment of the novel coronavirus infection. Earlier these pharmaceuticals were only permitted for use in a hospital setting, the press service of the Healthcare Ministry reported.
-
Russia’s Chumakov Center Gets Permission for Clinical Trials of its COVID-19 Vaccine
24 September 2020
The Chumakov Federal Scientific Center for Research and Development of Immune and Biological Products at the Russian Academy of Sciences received the Russian health ministry’s permit for clinical tests of its anti-coronavirus vaccine, the ministry’s press service said.
-
WHO Endorses Protocol for COVID-19 Herbal Medicine Clinical Trials
23 September 2020
The Regional Expert Committee on Traditional Medicine for COVID-19 formed by the World Health Organization (WHO), the Africa Centre for Disease Control and Prevention and the African Union Commission for Social Affairs has endorsed a protocol for phase III clinical trials of herbal medicine for COVID-19 as well as a charter and terms of reference for the establishment of a data and safety monitoring board for herbal medicine clinical trials.
-
Coronavir to Become the First COVID-19 Medicine Available in Pharmacies
23 September 2020
The R-Pharm group of companies has announced the approval of Coronavir (INN: favipiravir) for out-patient treatment of mild to moderate COVID-19 coronavirus infection. According to the marketing authorization issued (LP-006323), Coronavir has emerged as the first medicine for coronavirus infection in Russia to make it to pharmacies, becoming available to a broad population of out-patients.
-
22 September 2020
“International practice tells us that as soon as generic medicines appear, the healthcare system switches to them, and the released money is directed to the purchase of innovative medicines,” Timofey Nizhegorodtsev, Deputy Head of the FAS Russia said during the plenary session “Availability of innovative medicines for the patient. Legislation and practice”.
-
Favipiravir in Russia Received Permission for Outpatient Use
22 September 2020
Russia’s Healthcare Ministry has allowed the use of two favipiravir preparations for outpatient treatment of the novel coronavirus infection. Earlier these pharmaceuticals were only permitted for use in a hospital setting, the press service of the Healthcare Ministry reported.
-
The New Gold Standard of Drug Commercialization
21 September 2020
We find ourselves in a brave, new world. While institutional market sectors such as entertainment and hospitality struggle, life sciences find comfort in the promise of a rowing therapeutic pipeline. However, now more than ever, we must look for ways to streamline cost and mitigate risk. When working with established pharmaceutical companies or emerging entities, we recommend turning our clients’ attention away from traditional launch and commercialization approaches that may not stand the test of time.
-
Pharmaceutical Companies Must Publish Clinical Data for COVID-19 Related Products
21 September 2020
The European Medicines Agency (EMA) this week announced it will require drugmakers to publish clinical data for medicines and vaccines authorized to treat or prevent coronavirus disease (COVID-19) as part of its exceptional transparency measures during the pandemic.
-
Second Russian COVID-19 Vaccine Forms an Immune Response among a Wide Variety of Coronavirus Types
18 September 2020
The second Russian COVID-19 vaccine created by the State Research Center of Virology and Biotechnology “Vector” forms immunity to the virus for at least six months, the chief of the center’s zoonotic infections and influenza section, Alexander Ryzhikov, said.
-
The Novel Technology Will Enable Simplification of the Production Process for Nano-capsules
18 September 2020
The group of the scientists of BelSU Department for General Chemistry and Food Technology developed a new method to produce red cabbage anthocyanin nano-capsules in chitosan. The novel technology will enable simplification of the production process for nano-capsules used in pharmaceutical industry and increase their quality, exclude raw material losses in production.
Shareholders
Pipeline
Media Center
-
Favipiravir in Russia Received Permission for Outpatient Use
24 September 2020
-
Russia’s Chumakov Center Gets Permission for Clinical Trials of its COVID-19 Vaccine
24 September 2020
-
WHO Endorses Protocol for COVID-19 Herbal Medicine Clinical Trials
23 September 2020
-
Coronavir to Become the First COVID-19 Medicine Available in Pharmacies
23 September 2020